NCT05253105View on ClinicalTrials.gov

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 15, 2022

Primary Completion Date

September 30, 2026

Study Completion Date

January 31, 2027

Conditions
Previously Treated, AdvancedMalignancies
Interventions
DRUG

TAB006

Recombinant humanized, IgG4κ (immunoglobulin gamma 4, kappa) monoclonal antibody (mAb) that specifically binds to the T cell immunoreceptor with Ig and ITIM domains (TIGIT))

DRUG

Toripalimab

a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)

Sponsors
All Listed Sponsors
collaborator

TopAlliance Biosciences, Inc.

UNKNOWN

collaborator

CTI Clinical Trial and Consulting Services

OTHER

lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER